CRBU (Caribou Biosciences) Piotroski F-Score: 2 (As of Jun. 29, 2026) — Near Median


CRBU Caribou Biosciences Inc CRBU
66 GF Score
Price $1.67
GF Value $1.70
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Piotroski F-Score?

Caribou Biosciences CRBU +7.01% 66 Piotroski F-Score is 2 as of Jun. 29, 2026, which is at its 10-year median of 2.00. GuruFocus rates CRBU with a GF Score™ of 66/100 and a GF Value™ of $1.70 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,339 Biotechnology companies, Caribou Biosciences ranks worse than 73.04% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Caribou Biosciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Caribou Biosciences's Piotroski F-Score or its related term are showing as below:

CRBU' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 4
Current: 2

During the past 7 years, the highest Piotroski F-Score of Caribou Biosciences was 4. The lowest was 1. And the median was 2.

Caribou Biosciences  (NAS:CRBU) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Caribou Biosciences Piotroski F-Score Related Terms


Caribou Biosciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Piotroski F-Score Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 4.00 2.00 3.00 1.00 2.00

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 2.00 2.00 2.00

CRBU vs YDES, PRQR, CRBP: Piotroski F-Score Comparison

For the Biotechnology subindustry, Caribou Biosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caribou Biosciences Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Piotroski F-Score falls into.


CRBU
66GF Score
Caribou Biosciences Inc CRBU
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -54.098 + -27.548 + -26.488 + -25.085 = $-133.22 Mil.
Cash Flow from Operations was -28.258 + -25.185 + -20.824 + -26.984 = $-101.25 Mil.
Revenue was 2.667 + 2.198 + 3.941 + 2.397 = $11.20 Mil.
Gross Profit was 2.667 + 2.198 + 3.941 + 2.397 = $11.20 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(273.656 + 220.903 + 194.984 + 175.367 + 148.998) / 5 = $202.7816 Mil.
Total Assets at the begining of this year (Mar25) was $273.66 Mil.
Long-Term Debt & Capital Lease Obligation was $25.66 Mil.
Total Current Assets was $122.38 Mil.
Total Current Liabilities was $19.67 Mil.
Net Income was -37.697 + -34.684 + -35.49 + -39.991 = $-147.86 Mil.

Revenue was 3.464 + 2.024 + 2.077 + 2.353 = $9.92 Mil.
Gross Profit was 3.464 + 2.024 + 2.077 + 2.353 = $9.92 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(406.825 + 372.938 + 344.334 + 313.313 + 273.656) / 5 = $342.2132 Mil.
Total Assets at the begining of last year (Mar24) was $406.83 Mil.
Long-Term Debt & Capital Lease Obligation was $24.32 Mil.
Total Current Assets was $217.32 Mil.
Total Current Liabilities was $28.49 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Caribou Biosciences's current Net Income (TTM) was -133.22. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Caribou Biosciences's current Cash Flow from Operations (TTM) was -101.25. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-133.219/273.656
=-0.48681191

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-147.862/406.825
=-0.36345357

Caribou Biosciences's return on assets of this year was -0.48681191. Caribou Biosciences's return on assets of last year was -0.36345357. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Caribou Biosciences's current Net Income (TTM) was -133.22. Caribou Biosciences's current Cash Flow from Operations (TTM) was -101.25. ==> -101.25 > -133.22 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=25.659/202.7816
=0.12653515

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=24.323/342.2132
=0.07107558

Caribou Biosciences's gearing of this year was 0.12653515. Caribou Biosciences's gearing of last year was 0.07107558. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=122.381/19.673
=6.22075942

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=217.323/28.491
=7.62777719

Caribou Biosciences's current ratio of this year was 6.22075942. Caribou Biosciences's current ratio of last year was 7.62777719. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Caribou Biosciences's number of shares in issue this year was 95.862. Caribou Biosciences's number of shares in issue last year was 92.679. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=11.203/11.203
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9.918/9.918
=1

Caribou Biosciences's gross margin of this year was 1. Caribou Biosciences's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=11.203/273.656
=0.04093826

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=9.918/406.825
=0.02437903

Caribou Biosciences's asset turnover of this year was 0.04093826. Caribou Biosciences's asset turnover of last year was 0.02437903. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+1
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Caribou Biosciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
Caribou Biosciences (CRBU) has a Piotroski F-Score of 2 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Caribou Biosciences and its competitors. This is near median its historical median of 2.00. Over the past decade, Caribou Biosciences' Piotroski F-Score has ranged from 1.00 to 4.00. According to the industry distribution chart, Caribou Biosciences ranks #978 out of 1339 companies in the Biotechnology industry, placing it in the top 73%.
Is Caribou Biosciences' Piotroski F-Score too high?
Caribou Biosciences' current Piotroski F-Score of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Caribou Biosciences' value of 2 is 33.3% below this industry median. Based on the distribution chart, Caribou Biosciences ranks #978 out of 1339 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caribou Biosciences has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Piotroski F-Score compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #978 out of 1339 companies for Piotroski F-Score. This places Caribou Biosciences in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Caribou Biosciences' value of 2 is 33.3% below this benchmark. Historically, Caribou Biosciences' own Piotroski F-Score has ranged from 1.00 to 4.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 3.00, Caribou Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Piotroski F-Score is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.70, compared to a current price of $1.67 — trading 1.8% below its estimated fair value. The current Piotroski F-Score is 2, which is near median its 10-year median of 2.00 and 33.3% below the Biotechnology industry median of 3.00. Caribou Biosciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Piotroski F-Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.67 is trading 1.8% below its estimated GF Value™ of $1.70. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Piotroski F-Score: 2 (near median its 10-year median of 2.00)
  • GF Value™: $1.70 vs. price of $1.67 (1.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs
  • Industry Position: 33.3% below the Biotechnology median (#978 of 1339)

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
66GF Score

Get the complete analysis for CRBU

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.67
Price
$1.70
GF Value